SCPHARMACEUTICALS INC (SCPH)
US8106481059 - Common Stock
scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
Generated 4Q 2023 net FUROSCIX® revenue of $6.1 million, at the upper end of the range provided in January and representing sequential growth of 61% from...
scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024
Management to host conference call and webcast at 4:30 p.m. ET
scPharmaceuticals to Participate in Two Upcoming Investor Conferences
BURLINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and...
Commit To Purchase scPharmaceuticals At $5, Earn 22.4% Annualized Using Options
scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue
Company anticipates Q4 2023 net FUROSCIX revenue to be approximately $5.9 to $6.1 million; full-year net FUROSCIX revenue of approximately $13.4 to $13.6...
scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
Generated net FUROSCIX® revenue of $3.8 million Ended Q3 2023 with cash, cash equivalents and short-term investments of $90.2 million Company to host...
scPharmaceuticals to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
Management to host conference call and webcast at 4:30 p.m. ET...
Commit To Purchase scPharmaceuticals At $5, Earn 24% Using Options
scPharmaceuticals Becomes Oversold (SCPH)
scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical...
Oversold Conditions For scPharmaceuticals (SCPH)
Oversold Conditions For scPharmaceuticals (SCPH)
Oversold Conditions For scPharmaceuticals (SCPH)
(NASDAQ:SCPH)
scPharmaceuticals press release (SCPH): Q2 GAAP EPS of -$0.36 beats by $0.01.Revenue of $1.63M beats by $0.01M.
scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
Generated net FUROSCIX® revenue of $1.6 million
scPharmaceuticals to Announce Second Quarter 2023 Financial Results on Thursday, August 10, 2023
Management to host conference call and webcast at 4:30 p.m. ET...
Notable Two Hundred Day Moving Average Cross - SCPH
Oversold Conditions For scPharmaceuticals (SCPH)
scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes
BURLINGTON, Mass., June 23, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and...
scPharma stock slips after sales update on Furoscix
scPharmaceuticals (SCPH) lost ~9% in the morning hours Wednesday after issuing an update on the commercial rollout of its heart failure therapy Furoscix. Read more here.
scPharmaceuticals to Present at the Jefferies Healthcare Conference
BURLINGTON, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and...
scPharmaceuticals GAAP EPS of -$0.28 beats by $0.08, revenue of $2.1M beats by $0.53M (NASDAQ:SCPH)
scPharmaceuticals press release (NASDAQ:SCPH): Q1 GAAP EPS of -$0.28 beats by $0.08.Revenue of $2.1M beats by $0.53M.
scPharmaceuticals Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
Announced launch and commercial availability of FUROSCIX® on February 20th Generated net FUROSCIX revenue of $2.1 million Ended Q1 2023 with cash, cash...